# Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

> **NCT06646978** · — · ENROLLING_BY_INVITATION · sponsor: **Poitiers University Hospital** · enrollment: 787 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia (CML)

## Interventions

- **DRUG:** Imatinib (STI571)

## Key facts

- **NCT ID:** NCT06646978
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-05-01
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 787 (ESTIMATED)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646978, "Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06646978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*